(i) a polycationic peptide, wherein the polycationic peptide comprises a sequence selected from the group consisting of SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 8;

(ii) an intervening polypeptide region conjugated to at least three chemotherapy agents, wherein the intervening polypeptide is selected from the group consisting of SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO:40, cystatin B, cystatin C, cystatin D, cystatin M, and a variant having one or more mutations selected from the group consisting of a G4W, a G4R, a V48D, a V48L, a G50S, a K71N, a S72G, a L73P, a L82R and a T83S mutation with respect to the numbering in SEQ ID NO: 40; and

(iii) a polyhistidine region.